SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

NCT ID: NCT07256236

Last Updated: 2025-12-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 89 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-15
• Study Completion Date: 2028-12-15

Brief Summary

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.

Detailed Description

Cervical cancer (CC) is a major global health concern. Current second-line options, including single-agent chemotherapy or PD-1/L1 inhibitors, provide limited benefit, with objective response rates (ORR) of only 5-29%. Patients with cervical adenocarcinoma, which constitutes 20-25% of cases, often have a poorer prognosis, and no specific treatments are recommended for this subtype.

QL1706, a novel dual anti-PD-1/CTLA-4 antibody, has been approved in China for the second-line treatment of CC. Separately, TROP2 is highly expressed in 88.7% of CC and is associated with poor prognosis. Sac-TMT, a TROP2-directed ADC, combined with an anti-PD-1 agent showed a promising ORR of 57.9% in a phase II study, without new safety signals.

Based on the unique mechanisms of action of Sac-TMT and QL1706, as well as the existing research data, their combination is expected to provide a better second-line treatment option for recurrent or metastatic CC. Therefore, we are applying to conduct this Phase II, multicenter, single-arm clinical study to evaluate the efficacy and safety of Sac-TMT in combination with QL1706 for the treatment of recurrent or metastatic CC, in order to improve clinical benefits for patients.

Conditions

Cervical Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SKB264+QL1706

Group Type: EXPERIMENTAL

Sacituzumab tirumotecan

Intervention Type: DRUG

intravenous (IV) infusion (4mg/kg, Q2W)

QL1706

Intervention Type: DRUG

intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological disease progression, occurrence of intolerable toxicity, the participant requests to discontinue treatment, or other treatment discontinuation criteria specified in the protocol are met (whichever occurs first). The maximum duration of administration for QL1706 is 24 months.

Interventions

Sacituzumab tirumotecan

intravenous (IV) infusion (4mg/kg, Q2W)

Intervention Type: DRUG

QL1706

intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological disease progression, occurrence of intolerable toxicity, the participant requests to discontinue treatment, or other treatment discontinuation criteria specified in the protocol are met (whichever occurs first). The maximum duration of administration for QL1706 is 24 months.

Intervention Type: DRUG

Other Intervention Names

SKB264; Sac-TMT; MK-2870

Eligibility Criteria

Inclusion Criteria

• Female, aged ≥18 years at the time of signing the informed consent form;
• Diagnosed with recurrent or metastatic cervical cancer [pathological types include squamous cell carcinoma, adenocarcinoma (excluding mucinous adenocarcinoma), and adenosquamous carcinoma, etc., with pathological report provided], and not suitable for radical treatments such as surgery or radiotherapy. Patients will be divided into the following two cohorts based on pathological type:

• Cohort 1: Cervical squamous cell carcinoma;
• Cohort 2: Cervical non-squamous carcinoma (including adenocarcinoma or adenosquamous carcinoma, and other types of cervical cancer)
• Have experienced failure of at least one prior line of platinum-based standard therapy or intolerance to platinum-based drugs in the recurrent or metastatic setting, or have experienced radiologically confirmed disease progression during or within 6 months after completion (≥4 cycles) of platinum-based neoadjuvant or adjuvant chemotherapy. Specific requirements are as follows:

(a) Failure of first-line platinum-based standard therapy: meeting any one of the following criteria: i. Radiologically confirmed disease progression during treatment; ii. Radiologically confirmed disease progression after completion of treatment, provided the patient had a response (Complete Response (CR)/Partial Response (PR)/Stable Disease (SD)) and received ≥4 cycles of treatment; (b) Investigator's judgment that the subject is intolerant to platinum-based drugs; (c) Radiologically confirmed disease progression during or within 6 months after completion (≥4 cycles) of platinum-based neoadjuvant or adjuvant chemotherapy. Weekly chemotherapy administered concurrently with radiotherapy for sensitization purposes should not be counted as chemotherapy cycles;

• According to RECIST (v1.1) criteria, at least one measurable lesion (non-lymph node lesion with longest diameter ≥10 mm, or lymph node lesion with short diameter ≥15 mm). Lesions previously irradiated should not be selected as target lesions; unless there are no other measurable lesions available, in which case a previously irradiated measurable lesion that has shown confirmed progression radiologically may be selected as a target lesion. Subjects with only skin lesions or bone lesions are not eligible;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to dosing;
• Expected survival period ≥12 weeks;
• Subjects must have recovered from all toxicities resulting from prior therapy (i.e., improved to Grade 0 or 1, or to the level specified in the eligibility criteria), except for toxicities not considered a safety risk (such as alopecia, vitiligo, and other asymptomatic laboratory abnormalities). Subjects with ≤ Grade 2 neuropathy will be evaluated on a case-by-case basis in consultation with the investigator;
• Adequate organ and bone marrow function (without transfusion, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to dosing), defined as follows:

1. Neutrophil count (NEUT#) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Hemoglobin ≥90 g/L;

2. Liver function: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 × ULN; for subjects with baseline liver metastases, ALT and AST ≤5 × ULN; Albumin ≥30 g/L; Total bilirubin (TBIL) ≤1.5 × ULN;

3. Renal function: Creatinine clearance (Ccr) ≥50 ml/min (calculated using the standard Cockcroft-Gault formula); Urine protein ≤1+; if urine protein ≥2+, then 24-hour urine protein quantification must be ≤1.0 g;

4. Coagulation function: International Normalized Ratio (INR), Activated Partial Thromboplastin Time (APTT), and Prothrombin Time (PT) ≤1.5 × ULN;

5. Cardiac left ventricular ejection fraction (LVEF) ≥50%.

• For female subjects of childbearing potential, must agree to use effective medical contraception measures from the time of signing the informed consent form until 6 months after the last dose;
• The subject voluntarily joins this study, signs the informed consent form, and is able to comply with the visits and related procedures stipulated in the protocol.

Exclusion Criteria

• Subjects who have had a known additional malignancy that is progressing or has required active treatment within the past 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, etc., that has undergone potentially curative therapy.
• Subjects with known leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or other active central nervous system (CNS) metastases. Subjects with brain metastases treated with local therapy may be enrolled if they meet the following criteria: clinically stable for at least 4 weeks, and no requirement for steroid treatment for at least 14 days prior to the first dose of study drug.
• Subjects with clinically significant cardiovascular diseases, such as: a) Presence of severe or uncontrolled cardiac disease or clinical symptoms requiring treatment within 6 months prior to the first study dose, including: congestive heart failure classified as New York Heart Association (NYHA) Class III or IV, unstable angina pectoris uncontrolled by medication, severe arrhythmia requiring drug treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia), and myocardial infarction; b) Previous history of myocarditis or cardiomyopathy; c) QTc interval > 480 ms based on baseline measurement.
• Subjects with severe and/or uncontrolled concurrent diseases, such as decompensated liver cirrhosis, nephrotic syndrome, uncontrolled hypertension or severe hypertension, clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
• Subjects diagnosed with active Hepatitis B or Hepatitis C.
• Subjects with known poorly controlled human immunodeficiency virus (HIV) infection, including HIV infection with a history of Kaposi's sarcoma and/or multicentric Castleman's disease.
• Subjects with known active tuberculosis.
• Subjects with a history of severe dry eye syndrome, meibomian gland dysfunction, blepharitis, or corneal diseases that affect timely corneal healing.
• Subjects with a known prior history of fistula of the female reproductive tract (e.g., vesicovaginal fistula, urethrovaginal fistula, vesicocervical fistula, etc.); subjects may be enrolled if the perforation or fistula has been treated with diversion surgery, resection, or repair, and the disease is considered by the investigator to have recovered or resolved.
• Subjects who have undergone major surgery (as defined by the investigator) within 30 days prior to the first dose of study treatment or have not recovered from prior surgery.
• Subjects with known allergy or hypersensitivity to the study drug or excipients; history of severe hypersensitivity to monoclonal antibodies.
• Subjects with a history of interstitial lung disease (ILD), or history of non-infectious pneumonitis requiring steroid treatment, or current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging during screening.
• Subjects with a history of allogeneic tissue/organ transplantation.
• Subjects with autoimmune disease that required systemic treatment within the past 2 years or requires immunosuppressive therapy during the study period. Subjects with controlled Type 1 diabetes, thyroiditis with normal thyroid function, hypothyroidism controlled well with hormone replacement therapy (HRT), or skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis) can be enrolled.
• Subjects who have previously received TROP2-targeted therapy, or any drug containing a topoisomerase I inhibitor, including antibody-drug conjugate (ADC) therapy.
• Subjects who have previously used any experimental anticancer vaccine, or any drug targeting T-cell co-stimulation pathways.
• Administration of a live vaccine within 30 days prior to the first dose of study treatment, or planned administration of a live vaccine during the study.
• Requirement for strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to the first dose of study treatment or during the study.
• Received any chemotherapy, radiotherapy, immunotherapy, or biologic therapy within 4 weeks prior to the first dose of study treatment; received small molecule tyrosine kinase inhibitors (TKIs), antitumor hormone therapy, systemic immunostimulants (including but not limited to interferon, IL-2), or Chinese herbal patent medicines with approved anti-tumor indications within 2 weeks prior to the first dose of study treatment.
• Received palliative radiotherapy to known metastatic sites within 2 weeks prior to the first dose of study treatment.
• Received systemic anti-infection therapy within 1 week prior to the first dose of study treatment.
• Any condition requiring systemic corticosteroid therapy (at doses >10 mg/day prednisolone or equivalent dose of similar drugs) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment. However, subjects using intranasal, inhaled, topical, or local corticosteroid injections (e.g., intra-articular injection), or using corticosteroids as premedication for hypersensitivity reactions can be enrolled.
• Women who are pregnant or breastfeeding.
• Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the subject's safety, or the interpretation of study results, or any other circumstance that the investigator considers inappropriate for participation in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Fujian Cancer Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

First Affiliated Hospital of Army Medical University

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Fujian Medical University Affiliated Second Hospital

Fuzhou, Fujian, China

Zhangzhou Affiliated Hospital of Fujian Medical University

Zhangzhou, Fujian, China

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, China

The Second Hospital of Dalian Medical University

Dalian, Liaoning, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

The Second Qilu Hospital of Shandong University

Jinan, Shandong, China

Shandong Provincial Hospital

Jinan, Shandong, China

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Affiliated Hospital of Jining Medical University

Jining, Shandong, China

Qilu Hospital of Shandong University(Qingdao)

Qingdao, Shandong, China

Shanxi Cancer Hospital

Taiyuan, Shanxi, China

Countries

China

Central Contacts

Qin Xu, Ph.D

Role: CONTACT

xuqin@fjmu.edu.cn

0591-0-62752366

Other Identifiers

SHINE

Identifier Type: -

Identifier Source: org_study_id